Hina Iftikhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hina Iftikhar has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Adam N. Grey
University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, Wales, UK
1 shared publicationAmbreen Iqbal Muhammad
Watford General Hospital, West Hertfordshire Hospitals NHS Trust, Watford, UK
1 shared publication- Andrew Achaiah
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford
1 shared publication Andrew J. E. Harries
Royal Glamorgan Hospital, Llantrisant, Cwm Taf University Health Board, Wales, UK
1 shared publication- Anthony J. Rostron
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
1 shared publication Anthony Y. K. C. Ng
Addenbrookes Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 10 February 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (3) , 2102522
Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey
Background: There is an emerging understanding that coronavirus disease 2019 (COVID-19) is associated with increased incidence of pneumomediastinum (PTM). We aimed to determine its incidence among patients hospitalised with COVID-19 in the UK and describe factors associated with outcome. Methods: A structured survey of PTM and its incidence was conducted from September 2020 to February 2021. UK-wide participation was solicited via respiratory research networks. Identified patients had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and radiologically proven PTM. The primary outcomes were to determine incidence of PTM in COVID-19 and to investigate risk factors associated with patient mortality. Results: 377 cases of PTM in COVID-19 were identified from 58 484 inpatients with COVID-19 at 53 hospitals during the study period, giving an incidence of 0.64%. Overall 120-day mortality in COVID-19 PTM was 195 out of 377 (51.7%). PTM in COVID-19 was associated with high rates of mechanical ventilation. 172 out of 377 patients (45.6%) were mechanically ventilated at the point of diagnosis. Mechanical ventilation was the most important predictor of mortality in COVID-19 PTM at the time of diagnosis and thereafter (p<0.001), along with increasing age (p<0.01) and diabetes mellitus (p=0.08). Switching patients from continuous positive airway pressure support to oxygen or high-flow nasal oxygen after the diagnosis of PTM was not associated with difference in mortality. Conclusions: PTM appears to be a marker of severe COVID-19 pneumonitis. The majority of patients in whom PTM was identified had not been mechanically ventilated at the point of diagnosis.
- 10 February 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (3) , 2102522
Open AccessPneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey
Background: There is an emerging understanding that coronavirus disease 2019 (COVID-19) is associated with increased incidence of pneumomediastinum (PTM). We aimed to determine its incidence among patients hospitalised with COVID-19 in the UK and describe factors associated with outcome. Methods: A structured survey of PTM and its incidence was conducted from September 2020 to February 2021. UK-wide participation was solicited via respiratory research networks. Identified patients had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and radiologically proven PTM. The primary outcomes were to determine incidence of PTM in COVID-19 and to investigate risk factors associated with patient mortality. Results: 377 cases of PTM in COVID-19 were identified from 58 484 inpatients with COVID-19 at 53 hospitals during the study period, giving an incidence of 0.64%. Overall 120-day mortality in COVID-19 PTM was 195 out of 377 (51.7%). PTM in COVID-19 was associated with high rates of mechanical ventilation. 172 out of 377 patients (45.6%) were mechanically ventilated at the point of diagnosis. Mechanical ventilation was the most important predictor of mortality in COVID-19 PTM at the time of diagnosis and thereafter (p<0.001), along with increasing age (p<0.01) and diabetes mellitus (p=0.08). Switching patients from continuous positive airway pressure support to oxygen or high-flow nasal oxygen after the diagnosis of PTM was not associated with difference in mortality. Conclusions: PTM appears to be a marker of severe COVID-19 pneumonitis. The majority of patients in whom PTM was identified had not been mechanically ventilated at the point of diagnosis.
- 24 August 2017
- Published by Springer Nature
- p. 759-769
Residential Area Power Management Using Genetic Algorithm and Biogeography Based Optimization in Smart Grid
- 24 August 2017
- Published by Springer Nature
- p. 759-769
Residential Area Power Management Using Genetic Algorithm and Biogeography Based Optimization in Smart Grid